跳到正文
原文
MedPage Today·· 2 天前精选AI 评分65

FDA加速批准neladalkib用于经治ALK阳性非小细胞肺癌

FDA Adds Another Player in ALK-Positive Lung Cancer

AI 导读

FDA于2026年11月17日给予第三代ALK抑制剂neladalkib(Nelkarmi)加速批准,用于既往接受过alectinib治疗或至少两种既往ALK酪氨酸激酶抑制剂及铂类化疗的晚期ALK阳性非小细胞肺癌患者。

推荐理由

原文明确说明FDA加速批准的事项与适用人群,读者可据此了解该药在ALKB抑制剂序列中的位置。

正文

— Among the indications, neladalkib approved in second-line after alectinib

November 17, 2026 • 3 min read

The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the seventh approved agent in a crowded therapeutic field.

The approval limits use to patients with unresectable locally advanced or metastatic ALK-positive NSCLC previously treated with alectinib (Alecensa) or at least two prior ALK tyrosine kinase inhibitors and platinum-based chemotherapy.

Support for the conditional approval came from 222 patients in the phase I/II single-arm ALKOVE-1 trial.

In the cohort of 67 patients who had only received alectinib in the metastatic setting, neladalkib induced responses in 49%, with a duration of response (DOR) of at least 6 months in 76% of the responding patients. For the cohort of 155 patients previously treated with two or more ALK inhibitors and platinum-based chemotherapy, 32% responded, with a DOR of at least 6 months for 69% of the responders. The proportion of responders with DORs of at least 12 months was 52% and 51% for the two cohorts, respectively.

"Patients with ALK-positive lung cancer are often treated with multiple targeted therapies over many years," said investigator Alice Shaw, MD, PhD, of Dana-Farber Cancer Institute in Boston, in a press release from drugmaker GSK. "Advances in treatment have brought us closer to the goal of managing ALK-positive lung cancer as a chronic condition, but balancing disease control and long-term tolerability remains a significant challenge. The approval of neladalkib provides an important new treatment option for patients."

An analysis reported at the 2026 American Society of Clinical Oncology (ASCO) meeting showed a response rate of 26% among patients with exposure to lorlatinib (Lorbrena), the only other approved third-generation ALK inhibitor, versus 46% in patients not previously treated with lorlatinib. DORs of at least 6 or 12 months in the lorlatinib-treated subgroup occurred in 68% and 54% of responders.

In the full cohort of patients presented at the meeting (median three prior lines of therapy), landmark analyses of progression-free survival (PFS) showed a 6-month PFS of 50%, 12-month PFS of 33%, and 18-month PFS of 28% for patients treated with neladalkib. Median PFS was 5.7 months, increasing to 14.5 months in patients not previously treated with lorlatinib. Additionally, a third of patients with brain metastases had objective responses with neladalkib.

At the ASCO meeting, invited discussant Angel Qin, MD, of the University of Michigan in Ann Arbor, said the ALKOVE-1 results suggest neladalkib has potential as an option in the post-lorlatinib setting, albeit with relatively modest activity, and a manageable side-effect profile.

The most common adverse events (AEs) were elevated liver enzymes, which occurred in almost half of patients and was grade ≥3 severity in 15-20% of patients. Other AEs occurring in at least 20% of patients were musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue. Prescribing information for neladalkib includes warnings and precautions for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity.

The ongoing phase III ALKAZAR trial of neladalkib in the first-line setting may provide more information about the drug's potential as upfront therapy in advanced ALK-positive NSCLC. A preliminary analysis from ALKOVE-1 at ASCO showed an objective response rate of 86% for patients with no prior ALK-targeted therapy.

来源:MedPage Today · medpagetoday.com